Effect of cannabidiol on drop seizures in the lennox–gastaut syndrome

New England Journal of Medicine

Volumn 378, Issue 20, 2018, Pages 1888-1897

  Devinsky, Orrin ^a,j   Patel, Anup D ^b,k   Cross, J Helen ^d   Villanueva, Vicente ^g   Wirrell, Elaine C ^h   Privitera, Michael ^c   Greenwood, Sam M ^e   Roberts, Claire ^e   Checketts, Daniel ^e   VanLandingham, Kevan E ⁱ   Zuberi, Sameer M ^f  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e Porton Down Science Park   (United Kingdom)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

^h MAYO CLINIC   (United States)

ⁱ GW Pharmaceuticals Ltd   (United States)

^j NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k NATIONWIDE CHILDREN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CANNABIDIOL; CLOBAZAM; LAMOTRIGINE; LEVETIRACETAM; PLACEBO; RUFINAMIDE; VALPROIC ACID; AMINOTRANSFERASE; ANTICONVULSIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DROP SEIZURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EPILEPTIC STATE; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; KETOGENIC DIET; LENNOX GASTAUT SYNDROME; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEIZURE; SENSITIVITY ANALYSIS; SOMNOLENCE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VAGUS NERVE STIMULATION; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; DOSE RESPONSE; MIDDLE AGED; ODDS RATIO; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTICONVULSANTS; CANNABIDIOL; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; LENNOX GASTAUT SYNDROME; MALE; MIDDLE AGED; ODDS RATIO; SEIZURES; TRANSAMINASES; YOUNG ADULT;

EID: 85047318201     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1714631     Document Type: Article

References (19)

1. Heiskala H. Community-based study of Lennox-Gastaut syndrome. Epilepsia 1997;38:526-31.
2. Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol 2009;8:82-93.
3. Kim HJ, Kim HD, Lee JS, Heo K, Kim DS, Kang HC. Long-term prognosis of patients with Lennox-Gastaut syndrome in recent decades. Epilepsy Res 2015;110: 10-9.
4. Panayiotopoulos C. Epileptic enceph-alopathies in infancy and early childhood in which the epileptiform abnormalities may contribute to progressive dysfunction. In: Panayiotopoulos C, ed. The epilepsies: seizures, syndromes and management. Oxfordshire, United Kingdom: Bladon Medical Publishing, 2005:137-206.
5. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99.
6. Camfield PR. Definition and natural history of Lennox-Gastaut syndrome. Epilepsia 2011;52:Suppl 5:3-9.
7. Douglass LM. Conclusions: long-term management of Lennox-Gastaut syndrome: future directions. Epilepsia 2011;52:Suppl 5:28.
8. Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label in-terventional trial. Lancet Neurol 2016;15: 270-8.
9. Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;376:2011-20.
10. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540-5.
11. Sabaz M, Cairns DR, Lawson JA, Nheu N, Bleasel AF, Bye AM. Validation of a new quality of life measure for children with epilepsy. Epilepsia 2000;41:765-74.
12. Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 2011;77: 1473-81.
13. Purcarin G, Ng YT. Experience in the use of clobazam in the treatment of Lennox-Gastaut syndrome. Ther Adv Neurol Disord 2014;7:169-76.
14. Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018;391:1085-96.
15. Rosenberg EC, Louik J, Conway E, Devinsky O, Friedman D. Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol. Epilepsia 2017;58(8):e96-e100.
16. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008;70:1950-8.
17. Ng YT, Conry J, Paolicchi J, et al. Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study. Epilepsy Behav 2012;25:687-94.
18. Devinsky O, Patel AD, Thiele EA, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology 2018 March 14 (Epub ahead of print).
19. Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 2015; 56:1246-51.